Casey Means and MAHA Remove the 'Public' From Public Health
The Office of the Surgeon General is responsible for communicating scientific information to the public and addressing public health issues. Means' record would normally be considered antagonistic toward this fundamental goal, but Trump has praised the nominee as having "impeccable 'MAHA' credentials." Means describes herself as someone who left "traditional medicine," and has expressed health beliefs that flirt with pseudoscience and closely align with those of Robert F. Kennedy Jr.
Co-author of Good Energy: The Surprising Connection Between Metabolism and Limitless Health and co-founder of Levels (a company that sells continuous glucose monitors), Means has peddled health claims that are questionable at best and dangerous at worst. Like other wellness influencers, she has dabbled in some Goop-esque activities, like consulting with a spiritual medium and taking part in a full moon ceremony, which are a little woo-woo but don't harm anyone else. Of greater consequence to public health is Means' skepticism of vaccines. She has also called birth control use "disrespect of life" and endorsed the supposed health benefits of raw milk. The prospect of having a surgeon general who believes such things is terrifying.
Beyond the pseudoscience, Means' general orientation toward health is out of touch with the needs of average Americans. She has built her career and reputation on promoting lifestyle choices such as healthy eating and exercise. From afar, her takes may appear sensible, and at times, even compatible with sound medical advice. A healthy diet and exercise are important, but they alone do not translate to good, humane policies.
Means has suggested that health issues like "depression, anxiety, infertility, heart disease, erectile dysfunction, type 2 diabetes, Alzheimer's dementia, [and] cancer" are "under our control and simpler than we think." Simpler for whom? An emphasis on lifestyle ultimately assigns structural and institutional problems to individual Americans to solve for themselves. In a country where wealth buys health, how many Americans can afford to insulate themselves and their families from risks of disease and disability? The federal minimum wage has been stagnant at $7.25 since 2009. Meanwhile, the cost of necessities like housing, food, and child care have increased precipitously.
WASHINGTON, DC - MAY 12: U.S. Health and Human Services Secretary Robert F. Kennedy Jr. speaks alongside President Donald Trump during a press conference in the Roosevelt Room of the White House on May 12,...
WASHINGTON, DC - MAY 12: U.S. Health and Human Services Secretary Robert F. Kennedy Jr. speaks alongside President Donald Trump during a press conference in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. MoreIn her "health wishlist" for the Trump administration, Means says we need leaders who will "inspire people to care about their health, the food they eat, and their fitness." Americans do not need inspiration. Americans need access. It is cruel to push the idea that people are unhealthy simply because they do not care. Our most urgent public health problems cannot be solved with personal empowerment and lifestyle choices. For instance, 7.2 million children live in food-insecure households. Meanwhile, the House of Representatives is planning to cut $12 billion from federally funded school meal programs.
Health care is also inaccessible to many Americans because, unlike many of its peer countries, the U.S. does not offer universal health coverage. Even for those who do have health insurance, coverage is often insufficient, causing many to accrue medical debt. The Trump administration has added new public health problems: the Food and Drug Administration recently suspended quality control for milk, the Department of Agriculture withdrew a proposal to reduce Salmonella in raw poultry products, and the Environmental Protection Agency has loosened restrictions on mercury pollution. Meanwhile, Kennedy continues to fuel vaccine hesitancy amid a national measles outbreak.
MAHA priorities are misaligned with public health needs. Means' sunny website—where she promotes her book, recipes, and newsletters—frames good health as an individual project. Means' wish list to the Trump administration proposes actions that would address processed foods, "Big Pharma," vaccine safety, alternative medicine, and paternalistic restrictions on SNAP. It is apparent that her and Kennedy's health concerns reflect the airy worries of the rich. Their brand of health care is for people who can choose to be healthy, people with the time and money to pursue health optimization, and people comfortable enough to be fussy over food dyes.
Pandering to the desires of the upper class, MAHA pushes products and services that are out of reach for the average American. The surgeon general is supposed to be the nation's doctor. Means is just an entrepreneur who peddles an expensive lifestyle.
Catherine Tan is an Assistant Professor in Sociology at Vassar College. She is the author of Spaces on the Spectrum: How Autism Movements Resist Experts and Create Knowledge, published by Columbia University Press.
The views expressed in this article are the writer's own.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
an hour ago
- Time Magazine
1 in 30 U.S. Teens Identify as Transgender
Nearly 3 million Americans identify as transgender, including one in 30 of those aged 13 to 17, according to a new report. But data on the country's trans community may soon be hard to come by, its authors warned, as the Trump Administration and a number of GOP-led states seek to limit the recognition, and rights, of transgender people. The UCLA Williams Institute has been publishing reports about transgender Americans since 2011, tracking information such as the race, ethnicity, age, regional location, and mental health of transgender individuals. Trans adults and youth make up 1% of Americans aged 13 and older and 3.3% of 13-to 17-year-olds, according to the institute's Wednesday report. Researchers found that younger adults, those aged 18 to 34, were more likely to identify as transgender than their older counterparts, making up more than 50% of the country's transgender population. For its initial 2011 report, the institute relied on just two state-level population surveys. Researchers noted that they have since been able to access broader and higher-quality data through the Centers of Disease Control and Prevention (CDC): To generate the most recent findings, they used data from the CDC 2021-2023 Behavior Risk Factor Surveillance System and 2021 and 2023 Youth Risk Behavior Survey. The report authors noted that the Youth Risk Behavior Survey in particular 'currently provides the best available data for our estimates of the size and characteristics of youth who identify as transgender in the U.S.' But the agency will no longer collect information on transgender people in compliance with President Donald Trump's Executive Order calling for federal recognition of only two biological sexes. Since Trump returned to office in January, information regarding trans people and health resources for LGBTQ+ people has been quietly removed or modified on federal websites. And the Department of Health and Human Services (HHS) has stepped away from its previous practice of supporting gender-affirming-care, in spite of numerous statements from all major medical associations in the U.S., including the American Medical Association and the American Academy of Pediatrics, declaring the care as best practice. In May, HHS called for 'exploratory therapy' or psychotherapy to treat individuals with gender dysphoria instead of the medically recommended care. Multiple states have also sought to restrict access to gender-affirming care, particularly for minors, amid broader global efforts to target such care for trans youth. A June Supreme Court decision upholding a Tennessee state-level ban on gender-affirming-care for youth delivered a heavy blow to the U.S. LGBTQ+ community, permitting similar bans that have been enacted across the country and presenting a significant obstacle to future efforts to challenge restrictions in the courts. Amid the current political climate, the authors of Wednesday's Williams Institute report say they are unsure whether survey respondents will accurately respond to questions regarding their gender identity moving forward. In addition to the uncertain future of data on the U.S. transgender population, they wrote, 'It is also unclear whether individuals' willingness to disclose on surveys that they identify as transgender will remain unchanged in the years to come.' Despite those looming challenges in gathering information, however, the authors noted it is already clear that younger people are more likely to identify as transgender and they anticipate that to continue being true. 'This has implications for institutions in our society, including educational institutions, the U.S. Armed Forces, civilian workplaces, health care settings, and other areas, regarding how to meet the needs of and provide opportunities for current youth and future generations,' they said.
The Hill
2 hours ago
- The Hill
2.8M in US now identify as transgender: Research
Roughly 2.8 million Americans aged 13 and older identify as transgender, accounting for approximately 1 percent of the U.S. population in that age group, according to a new estimate from the Williams Institute, a research organization focused on sexual orientation and gender identity issues. About three-quarters of people who identify as transgender in the U.S. are under 35, according to the report published Wednesday, and 25 percent are between 13 and 17. Williams Institute researchers used data from the Behavioral Risk Factor Surveillance System (BRFSS) and Youth Risk Behavior Surveillance System (YRBSS) — public health surveys administered by the Centers for Disease Control and Prevention (CDC) — and statistical modeling to estimate the population of trans adults and youth in all 50 states and Washington, D.C. About 2.1 million adults identify as transgender, accounting for approximately 0.8 percent of Americans aged 18 and older, according to Wednesday's report. Roughly 3.3 percent of 13 to 17-year-olds in the U.S., or 724,000, identify as transgender. 'Younger generations are more likely to identify as transgender, and we expect that trend to continue,' said Jody Herman, the report's lead author and a senior scholar at the Williams Institute. 'Youth and young adults are more likely to identify as transgender due to a variety of factors, including a greater willingness among younger individuals to disclose that they identify as transgender on surveys.' That finding is consistent with national surveys on LGBTQ identification. In a February Gallup poll, 23.1 percent of Gen Z said they identify as lesbian, gay, bisexual, transgender or 'something other than heterosexual,' compared with 14.2 percent of Millennials and 5.1 percent of Gen X. The Williams Institute, affiliated with the University of California, Los Angeles School of Law, has tracked the number of transgender people in the U.S. since at least 2011. In 2022, the group estimated that 1.6 million Americans identified as transgender. Most transgender people in the U.S. — about 279,000 — live in the South, according to Wednesday's report, consistent with previous years' findings. Around 175,000 transgender Americans live in the West; 156,000 in the Midwest and 114,000 in the Northeast, the Williams Institute found. Of all adults who identify as transgender, 33 percent are transgender women; 34 percent are transgender men and 33 percent are nonbinary, according to Wednesday's report. The group's estimate comes as President Trump's administration works to remove public health datasets and information from federal government websites about transgender people and identities. Affixed at the top of the CDC's webpage for the YRBSS, which the Williams Institute used in its calculation on Wednesday, is an advisory that 'Any information on this page promoting gender ideology is extremely inaccurate and disconnected from the immutable biological reality that there are two sexes, male and female.' 'The Trump Administration rejects gender ideology and condemns the harms it causes to children, by promoting their chemical and surgical mutilation, and to women, by depriving them of their dignity, safety, well-being, and opportunities,' the advisory reads. 'This page does not reflect biological reality and therefore the Administration and this Department rejects it.' Federal health agencies, including the CDC, were ordered to restore online datasets taken down after Trump issued an executive order in January prohibiting the government from promoting 'gender ideology.' Each of the restored webpages leads with notices condemning 'gender ideology.' The White House has also sought to remove questions about gender identity from national surveys on crime victimization and sexual violence. In February, former U.S. Census Bureau Director Robert Santos told NPR that the bureau had moved to strike gender identity questions from several surveys it conducts because of Trump's Jan. 20 order. 'Federal datasets that include questions about sexual orientation and gender identity have provided critical information to researchers, clinicians, policymakers, and the public,' Andrew R. Flores, a distinguished visiting scholar at the Williams Institute and one of the authors of Wednesday's report, said in a statement. 'Removal of these questions from federal surveys — such as the BRFSS and the YRBS — would significantly hinder the ability of researchers to assess the health, experiences, and needs of transgender people in the United States.'
Yahoo
2 hours ago
- Yahoo
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
